Related to IDT Buys 1st Base Custom Oligo Business to Serve Clients in Asia

• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• Astellas Enters Asian Licensing Agreement for Ironwood’s Phase III IBS Therapy with $30M
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Millipore Acquires Remaining Ownership of India JV
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Pfizer and Crown Team Up to Develop Treatments for Asian Cancers
  
• Kyowa Hakko Licenses Late-Stage Chronic Kidney Disease Drug from Reata for $35M
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• Qiagen and WuXi Join Forces to Support Biomarker Development in Asia
  
• Nacalai to Provide TriLink’s Nucleic Acid Products in Certain Asian Countries
  
• Roche Makes Near $95M Investment in Singapore-Based Center for Translational Medicine
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• PPD Continues Asia Expansion with Plans for New Facilities in the Philippines and India
  
• Lilly, Merck & Co., and Pfizer Establish Asian Cancer Research Group Focused on Lung and Gastric Cancers
  
• Kyowa Hakko Kirin to Sell Solasia’s Antiemetic Patch in Certain Asian Countries
  
• Cosmo Bio to Distribute Bio-Quant’s Discovery and Preclinical CRO Services in Japan
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China